You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Comparison between patients who died within 30 days of bacteremia diagnosis and patients who survived

From: Peripheral venous catheter-related bloodstream infection is associated with severe complications and potential death: a retrospective observational study

  Full cohort n(%) Died within 30 days n (%) Survived n (%) Odds ratio 95% CI P
Total 62 8(100) 54(100)    
Gender (male) 40 (64.5) 6 (75.0) 34 (63.0)    0.512
Age, median (years) 69 (range; 1–92) 76 (range; 52–86) 69 (range; 1–92)    0.126
Duration from admission to bacteremia, median (days) 17 (range; 3–142) 33(range; 9–142) 16(range; 3–86)    0.089
Duration of antibiotic therapy from diagnosis of PVC-BSI, median (days) 16 (range; 5–100) 17(range; 7–46) 16(range; 3–100)    0.737
Time from catheter insertion to bacteremia, median (days) 6 (range; 2–15) 7 (range; 2–9) 7 (range; 3–15)    0.526
 Unknown 26 (41.9) 2 (25.0) 24 (44.4) 0.42 0.08–2.25 0.298
  < 3 days 4 (11.1) 2 (25.0) 2 (3.7) 8.67 1.03–73.25 0.022
 4–7 days 19 (52.8) 1(16.7) 18 (66.7) 0.29 0.03–2.50 0.232
  > 8 days 13 (36.1) 3(50.0) 10 (30.0) 2.64 0.54–12.91 0.218
Causative microorganism (including duplicate polymicrobials)
 Gram-positive microorganisms 47(58.0) 7(77.8) 40(54.8) 2.45 0.28–21.72 0.408
S.aureus 14(17.3) 5(62.5) 9(16.7) 8.33 1.68–41.29 0.004
 MSSA 10(71.4) 3(37.5) 7(12.7) 4.03 0.78–20.70 0.078
 MRSA 4(28.6) 2(25.0) 2(3.7) 8.67 1.03–73.25 0.022
 CNS 21(25.9) 2(25.0) 16(29.6) 0.79 0.14–4.35 0.788
Bacillus spp. 6(7.4) 0 6(11.1) 0.44 0.02–8.53 0.576
Enterococcus spp. 6(7.4) 0 6(11.1) 0.44 0.02–8.53 0.576
 Gram-negative microorganisms 30(35.8) 2(22.2) 28(38.4) 0.31 0.06–1.67 0.156
Enterobacter spp. 9(11.1) 0 6(11.1) 0.44 0.02–8.53 0.576
Klebsiella spp. 5(6.2) 1(12.5) 4(7.4) 1.79 0.17–18.35 0.621
Pseudomonus spp. 4(4.9) 1(12.5) 3(5.6) 2.43 0.22–26.69 0.455
Acinetobacter spp. 4(4.9) 0 4(7.4) 0.66 0.03–13.40 0.785
Serratia spp. 4(4.9) 0 4(7.4) 0.66 0.03–13.40 0.785
E.coli 3(3.7) 0 3(5.6) 0.87 0.04–18.29 0.926
Citrobacter spp. 1(1.2) 0 1(1.9) 2.10 0.08–55.84 0.651
Candida spp. 5(6.2) 0(0.0) 5(6.8) 0.53 0.03–10.48 0.671
 Polymicrobial 16(25.8) 1(12.5) 15(27.8) 0.37 0.04–3.28 0.357
Underlying diseases (including duplicate)
 Malignancy 33 (53.2) 4(50.0) 26(48.1) 1.08 0.24–4.76 0.922
 Hypertension 14 (22.6) 0 14 0.16 0.01–0.03 0.172
 Diabetes mellitus 11 (17.7) 0 11 0.22 0.01–4.15 0.274
 Cerebral infarction 7 (11.3) 2(25.0) 5(9.3) 3.27 0.52–20.69 0.189
 Orthopedic disorder 3 (4.8) 0 3 (5.6) 0.87 0.04–18.29 0.926
Department
 Surgery 35 (56.5) 3(37.5) 32(59.3) 0.41 0.09–1.91 0.247
 Internal medicine 21 (33.9) 5(62.5) 16(29.6) 3.96 0.84–18.57 0.067
 Obstetrics and Gynecology 5 (8.1) 0 5 (9.3) 0.53 0.03–10.48 0.672
 Pediatrics 1 (1.6) 0 1 (1.9) 2.10 0.08–55.84 0.651
Place of insertion
 Arm 48 (77.4) 7 (87.5) 41 (75.9) 2.22 0.25–19.76 0.465
 Foot 3 (4.8) 1(12.5) 2 (3.7) 3.71 0.30–46.48 0.279
 Unknown 11 (17.7) 0 11 (20.4) 0.22 0.01–4.15 0.274
Complication
 Suppurative thrombophlebitis 18 (29.0) 3(37.5) 15(27.8) 1.56 0.33–7.35 0.572
 Bacterial cellulitis 3 (4.8) 2 (25.0) 1 (1.8) 17.67 1.39–225.05 0.004
 Osteomyelitis 2 (3.2) 0 2 (3.7) 1.24 0.05–28.02 0.894
  1. Abbreviations: S. aureus, Staphylococcus aureus; MSSA, Methicillin-sensitive S. aureus; MRSA, Methicillin-resistant S. aureus; CNS, coagulase-negative Staphylococcus; P. aeruginosa, Pseudomonus aeruginosa; E. coli, Escherichia coli
  2. Footnote: Some of the patients included in our study had multiple diseases. When we calculated the incidence of each underlying disease, we included the patients with multiple underlying diseases in all relevant calculations, so some patients were counted more than once